New immune therapy drug enters human testing for tough cancers
Disease control
Completed
This first-in-human study tested a new experimental drug called HMBD-002, which targets a protein on cancer cells called VISTA. The trial aimed to find a safe dose and schedule for giving HMBD-002 alone and combined with the approved immunotherapy drug pembrolizumab (Keytruda®) i…
Phase: PHASE1 • Sponsor: Hummingbird Bioscience • Aim: Disease control
Last updated Mar 11, 2026 14:53 UTC